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Abstract: Atrophie blanche can be a chronic condition for
which there is no satisfactory treatment. Two patients with
atrophie blanche who had not responded to various therapeu-
tic modalities were given a trial of sulfasalazine 1 g three times
daily. The ulcers healed within 3 months in both cases. In view
of these positive results, patients should be treated with sulfa-
salazine to determine the efficacy of this drug in atrophie
blanche.
Atrophie blanche was first described by Milian in
1926.' Others'-'' have preferred the term livedo vascu-
litis or segmental hyalinizing vasculitis for this condi-
tion. It is a chronic disorder that is more common in
young and middle-aged women and usually affects the
lower legs and ankles. Uncommonly, lesions may
occur on the hands, face, and trunk. There is usually
no underlying systemic disease. The salient pathologic
findings include the occurrence of fibrinoid material in
superficial blood vessels, decreased vascularity," and
intimal proliferation as well as hyalinization of the
blood vessel walls.^'^ However, there are no uniformly
accepted clinical or histopathologic criteria for this
condition.''-^ We report the successful use of sulfasala-
zine in two patients with atrophie blanche (livedo vas-
culitis), a condition in which none of the numerous
reported treatments has been consistently effective.''""**
Case 1
• An 18-year-old white woman presented in August 1988
with a 3-year history of painful, multiple ulcerations of
both her lower legs. For the previous 2 weeks, the pain
had been worsening with a decreasing range of motion
of the right ankle, necessitating the use of crutches. The
patient was otherwise in excellent health and had no
symptoms of collagen vascular or Raynaud disease. Past
therapies included trials of pentoxifylline, nifedipine.
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ibuprofen, and naproxen, all of which had been of no
therapeutic benefit.
On examination, there was erythema and edema of
the lower aspects of both legs and ankles. Numerous
purpuric macules and papules were noted with multiple
punched-out irregularly shaped, tender ulcerations,
8-15 mm in diameter (Fig. 1 A). There were also areas of
stellate, ivory-colored, atrophie scars, some of which had
a hyperpigmented border with telangiectasias. The dis-
ease affected the right leg to a greater extent than the left.
The range of active motion of the right ankle was mark-
edly reduced. She had normal peripheral pulses and no
evidence of varicosities or stasis dermatitis.
Laboratory investigation, including CBC. SMA12,
ANA, complement levels, eryoglobulins, seium protein
electrophoresis, VDRL, and urinalysis were negative or
within the normal range. An x-ray of the right ankle was
normal. Histology was consistent with alrophie blanche
and revealed intravascular fibrinoid deposits and promi-
nent hyalinization of the middle and deep dermal vessel
walls.
The patient was started on sulfasalazine 500 mg tid
for 3 days, followed by 1 g tid. The only topical treat-
ment used by the patient eonsisted of the daily applica-
tion of a dry dressing. At pretherapy, the patient was
taking acetaminophen 4.2 g daily for pain control.
Within 10 days, there was improvement with a marked
decrease in pain and the patient was able to discontinue
the acetaminophen. By 3 weeks, some of the ulcers were
beginning to heal with a decrease in erythema and
edema of the legs. At this point, the patient was able to
ambulate without crutches. After completing 6 weeks of
therapy without any side etfects, the ulcers were com-
pletely healed and the patient elected to discontinue the
medication. All the improvement occurred using sulfa-
salazine as monotherapy, without bed rest or the use of
stockings. She returned 5 months later, off therapy,
without any recurrence of the lesions (Fig. IB).
Case 2
A 33-year-old black woman presented in September
1988 with a 5-year history of tender, chronic ulcers of
the lower aspects of the legs. There had been an increase
in the number of ulcers and worsening pain over the
previous 6 weeks, to the extent that she was now house-
bound and had to use a wheelchair. She had hyperten-
sion, which was controlled with hydralazine 25 mg tid.
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Figure 1. Case 1: atrophie blanche at (A, left) pretherapy and (B,
right) 5 months following a 6-week course of sulfasalazine 1 g three
times a day.
verapamil hydrochioride SR 240 mg bid, and hydro-
ehlorthiazide 50 mg daily. The patient was otherwise in
good health, with no evidence of collagen vascular dis-
ease. Past treatments had been unsuccessful and in-
cluded topical and oral corticosteroids, pentoxifylline,
aspirin, oral erythromycin, and local dressings.
On examination, the clinical picture was similar to
that described in case 1, except that there were a greater
number of white, atrophic scars (Figure 2 A). Peripheral
pulses were normal and there was no evidenee of stasis
dermatitis or varicose veins.
Laboratory investigations included CBC, SMA12,
ANA, complement levels, eryoglobulins, urinalysis, an-
ticardiolipin antibody and coagulation studies, which
were all negative or within the normal range. A biopsy
from an active ulcer site was consistent with atrophie
blanche, with the sahent findings being similar to those
in case 1.
The patient was commenced on sulfasalazine 500
mg tid for 3 days, followed by 1 g tid, which was well
tolerated. As in the previous case, the only topical ther-
apy was the daily use of dry dressings. For pain relief, the
patient was using propoxyphene 130 mg daily. Healing
of the ulcers and a decrease in erythema and pain oc-
curred after 6 weeks of therapy. The patient was now
able to discontinue use of the wheelchair and propoxy-
phene. After 12 weeks of therapy, all the lesions had
healed with no new ones forming over the last 7 weeks
(Fig. 2B). At this point, we were able to discontinue
sulfasalazine. Prior to the therapy and throughout the
treatment course, the patient continued to preform nu-
merous household tasks due to her responsibilities as a
homemaker. She was never able to be on bed rest and
did not use stockings; her only therapy was sulfasalazine.
Discussion
Therapies that have been reported for atrophie blanche
(livedo vasculitis) include medical treatments such as
bed rest, elastic stockings,^'° silver nitrate cautery,'-"*
topical, intralesional, and oral corticosteroids,^'^-'° an-
tiplatelet therapy with aspirin and dipyridamole,'"-"
fibrinolytics such as phenformin and ethylestrenol,'
warfarin'^ and minidose heparin,'^ nifedipine,''' nico-
tinic acid,'^ anti-inflammatory agents,'^ sulfapyri-
dine,^''^ and pentoxifylline."'''^ Surgical therapies in-
clude sympathectomy^-'^ as well as excision followed
by skin grafting.'* Both our patients previously failed
therapy with some of the above modalities, underlin-
ing the fact that none of the present therapies are com-
pletely satisfactory.
The two cases we have presented were substan-
tially physically incapacitated prior to starting sulfasal-
Figure 2. Case 2: atrophie blanche at (A, left) pretherapy and (B, right) 3 months following a
12-week course of sulfasalazine 1 g three times a day.
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azine. A clinical response with sulfasalazine therapy
was first noted within 3 weeks in both cases, with com-
plete healing at 6 weeks in one case and 12 weeks in the
other. The mechanism of action of sulfasalazine in
atrophie blanche is not clear. The active moiety may
be the parent drug itself, its metabolites, or a combina-
tion of the two. Approximately 10-15% of sulfasala-
zine is absorbed in the small bowel.'** The remainder is
metabolized in the large bowel to 5-aminosalicylic acid
and sulfapyridine; 5-aminosalicylic acid (5-ASA) may
reduce formation of cycloxygenase products in human
colonic mucosa, including thromboxane AT,^"'^' a
stimulator of platelet aggregation. Whether these ef-
fects also occur in derrnal vessels is not known. In
addition, the other moiety, sulfapyridine, has been
previously reported to be beneficial in some patients
with atrophie blanche,"'^ possibly by acting as an anti-
inflammatory agent through its effects on polymor-
phonuclear leukocyte function^- and as a thrombox-
ane inhibitor at high concentrations.^^ Furthermore,
the parent compound can also inhibit thromboxane
synthetase in platelets^"'^' and partially inhibit cy-
clooxygenase."' Another possibility is that sulfasala-
zine may prevent cytokine release from human mono-
nuclear cells,̂ "* and thereby inhibit platelet aggrega-
tion.̂ -̂̂ * For these reasons, sulfasalazine may be a
preferred treatment over monotherapy with sulfapyri-
dine or the nonsteroidal anti-inflammatory drugs. Fur-
ther studies are necessary to understand the mecha-
nism of action of sulfasalazine in this disease.
Atrophie blanche may have spontaneous remis-
sions and exacerbations. Although possible, we think it
is extremely unlikely that the improvement first seen
in our patients within 3 weeks of starting sulfasalazine
therapy was due to spontaneous disease fluctuation.
Sulfasalazine is a relatively inexpensive drug with a
low incidence of severe side effects. Whatever the exact
mechanism of action of sulfasalazine, in view of our
preliminary positive results, further trials are war-
ranted in atrophie blanche, a disease that can have a
chronic debilitating course and one currently without
consistently effective therapy.
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